A Randomized, Single-center, Double-blind, Placebo-controlled Study to Explore the Effect of a Single Dose of Certolizumab Pegol 400mg on Semen Quality in Healthy Male Volunteers.

Trial Profile

A Randomized, Single-center, Double-blind, Placebo-controlled Study to Explore the Effect of a Single Dose of Certolizumab Pegol 400mg on Semen Quality in Healthy Male Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Oct 2014

At a glance

  • Drugs Certolizumab pegol (Primary)
  • Indications Crohn's disease; Plaque psoriasis; Rheumatoid arthritis
  • Focus Pharmacodynamics
  • Sponsors UCB
  • Most Recent Events

    • 09 Jun 2012 Results presented at the 13th Annual Congress of the European League Against Rheumatism.
    • 01 Jun 2012 Results are to be presented at the 13th Annual Congress of the European League Against Rheumatism (EULAR-2012), according to a UCB media release.
    • 31 Mar 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top